Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
Press Release|Articles|December 17, 2024
Camber Pharmaceuticals Announces Addition of Erlotinib Tablets
Listen
0:00 / 0:00
Erlotinib Tablets are available in 25 mg, 100 mg, and 150 mg strengths, packaged in 30-count bottles.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Erlotinib Tablets.
Erlotinib Tablets are a kinase inhibitor indicated for:
- The treatment of patients with metastatic non-small cell lung cancer (NSCLC)
- First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Erlotinib Tablets are available in 25 mg, 100 mg, and 150 mg strengths, packaged in 30-count bottles.
To find out more information on Erlotinib Tablets please visit:
Advertisement
Related to this article
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
A current pharmacy resident provides insights on how pharmacy students can manage the transition from student to resident.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
2
Beyond Prescription Volume: Measuring the Pharmacist’s Value
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5